Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B - Lim, Young-Suk; Chan, Henry L.Y.; Ahn, Sang Hoon; Seto, Wai Kay; Ning, Qin; Agarwal, Kosh; Janssen, Harry L.A.; Pan, Calvin Q.; Chuang, Wan Long; Izumi, Namiki; Fung, Scott; Shalimar; et al. (JHEP reports, 2023)
Keywords: aMAP; antiviral therapy; Gastroenterology and Hepatology; incidence; mPAGE-B; REACH-B; ETV; HBeAg; ALT; HCC; HR; mPAGE-B; SIRs; NA; aMAP; TDF; REACH-B; TAF; CHB; incidence; HBV; OL; antiviral therapy; DB; hepatitis B virus; open-label; alanine aminotransferase; tenofovir alafenamide; double-blind; hepatocellular carcinoma; chronic hepatitis B; entecavir; tenofovir disoproxil fumarate; standard incidence ratios; Hepatitis B e antigen; nucleot(s)ide analogue; hazard ratio